Wells Fargo
SMMT icon

Wells Fargo’s Summit Therapeutics SMMT Stock Holding History

Wells Fargo’s Portfolio SMMT Stock Details SMMT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-100
Closed -$2.07K – 7327
2025
Q3 		$2.07K Buy
+100
New +$2.42K ﹤0.01% 6181

Other funds holding SMMT

BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return

Wells Fargo's SMMT Position: Q2 2026 in Review

Wells Fargo increased its Summit Therapeutics (SMMT) stake by 73% in Q2 2026, buying an estimated $1.56M and bringing the position to 208,413 shares worth $3.04M. The position accounts for ﹤0.01% of the portfolio, ranked #3263.

Wells Fargo first reported a position in SMMT in Q3 2015 and has held it in 34 quarters since. The position peaked at $4.99M in Q2 2025. 242 funds tracked by Wall St. Rank hold SMMT as of Q2 2026.

  • Wells Fargo held 208,413 shares of Summit Therapeutics worth $3.04M as of Q2 2026.
  • Wells Fargo bought 88,112 Summit Therapeutics shares in Q2 2026, an estimated $1.56M.
  • Summit Therapeutics made up ﹤0.01% of Wells Fargo's portfolio in Q2 2026, its #3263 holding.
  • Wells Fargo first reported a position in Summit Therapeutics in Q3 2015 and has held it in 34 quarters since.
  • Wells Fargo's Summit Therapeutics position peaked at $4.99M in Q2 2025.
  • 242 funds tracked by Wall St. Rank held Summit Therapeutics as of Q2 2026.

Based on Wells Fargo's 13F filing for Q2 2026, filed 14 Aug 2026.